The pharmaceutical group Saidal has set up its first bioequivalence center which will start operating “in less than two weeks”, declared Fatoum Akacem, CEO of the pharmaceutical group, on Radio Chaine III.
“This center is used to demonstrate that a generic drug is a true copy of the parent molecule (…) which will greatly facilitate the export of Algerian pharmaceutical products since it is an important regulatory requirement”, said delighted, Fatum Akacem.
“The center will be called upon to carry out bio-equivalence for multinationals operating in Algeria”, specifies a manager.
According to her, the center is “composed of local Algerian skills” and “is open, for the future, to national skills established abroad”.
“Two million doses of CoronaVac produced”
While the production of Chinese vaccine in Algeria was launched on September 29, the CEO of the Saidal group said that 2 million doses of vaccines have been produced so far. The Ministry of Pharmaceutical Industry recently announced the start of the marketing of the said vaccine.
“We can produce, according to our contract with the Chinese partner, up to 96 million doses per year,” she said.
A quantity “which will satisfy and the national market is international”, estimates Fatoum Akacem.
On the export side, continues the manager, the targeted markets are the countries of West Africa and Central Africa in negotiation with the Chinese partner, as stipulated by the contract binding the two parties.
“We can already export, but some countries require accreditation from the WHO (World Health Organization, editor’s note), explains the CEO of Saidal, specifying that the exchanges have progressed well and a WHO expert is expected shortly. in Algeria.
pipanews.com and APS January 16, 2022
